Clinical role and mechanism of miR-4443 in coronary heart disease: a prognostic marker and regulator of vascular smooth muscle cell Function Authors: Rongguo Sun, Jichun Hao, Guowei Jia, Fei Liu, Shutian Song Published: 2026 ABSTRACT BackgroundDysregulation of vascular smooth muscle cell (VSMC) function is a key factor in coronary heart disease (CHD) pathogenesis. This study investigates the role of miR-4443 in regulating VSMC behavior and its potential as a clinical biomarker.MethodsClinical data from 200 CHD patients were retrospectively analyzed. miR-4443 expression levels were quantified via RT-qPCR in paired plasma specimens and in VSMC exposed to oxidized low-density lipoprotein (ox-LDL). Prognostic relevance was evaluated through Kaplan-Meier analysis and multivariate Cox regression modeling. Cellular transfection, CCK-8, Transwell, and dual-luciferase reporter assays were employed to evaluate VSMC proliferation, migration, and gene regulatory mechanisms.ResultsCHD patients exhibited significantly higher serum levels of miR‑4443 relative to healthy controls. Univariate analysis revealed significant associations between the risk of major adverse cardiovascular events (MACEs) and miR‑4443, BMI, LDL‑C, and CRP. After multivariable adjustment, elevated miR‑4443 expression retained independent prognostic value for adverse outcomes (HR = 2.812, 95% CI: 1.130–6.997, P = 0.026). Kaplan-Meier analysis revealed an elevated cumulative incidence of MACEs in patients exhibiting high miR-4443 levels relative to those with low expression. In ox-LDL-induced VSMCs, miR-4443 expression was upregulated. Functionally, miR-4443 promoted VSMC proliferation and migration, while its inhibition suppressed these processes. TIMP2 expression was reduced in CHD patients. Furthermore, luciferase reporter assays confirmed TIMP2 as a direct target of miR-4443, through which miR-4443 regulates VSMC function.ConclusionmiR-4443 functions as a prognostic biomarker in CHD by targeting TIMP2 to regulate VSMC proliferation and migration, highlighting its dual diagnostic and therapeutic potential.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13019-026-04391-4. Introduction Coronary heart disease (CHD) is the main pathological feature of atherosclerosis, which is essentially a chronic pathological change closely related to inflammation, eventually leading to myocardial ischemia, hypoxia and even necrosis [1]. Although primarily a condition of adults beyond the age of 40, the incidence of CHD in young people has been increasing in recent years. Its morbidity and mortality rank the first among all kinds of chronic non-communicable diseases, representing a major threat to population health and a significant economic burden for patients and society [2, 3]. Coronary heart disease is affected by a variety of risk factors [4]. In terms of treatment, revascularization is one of the most effective means. While coronary heart disease lacks a definitive cure, revascularization procedures substantially alleviate symptoms while enhancing both quality of life and long-term survival [5]. The principal revascularization strategies employed clinically are coronary artery bypass grafting and percutaneous coronary intervention (PCI) [6]. The rapid development of PCI technology and the continuous emergence of new anticoagulant and antiplatelet drugs, its indications continue to expand, and the treatment exclusion zone is gradually broken through [7]. Evidence indicates that aberrant VSMC proliferation constitutes a central event in the pathogenesis of numerous cardiovascular diseases, including CHD [8, 9]. However, the molecular mechanisms underlying VSMC proliferation and migration have not been fully elucidated. Therefore, it is of great clinical significance to find biomarkers that can objectively and accurately evaluate the severity and complexity of CHD. MicroRNAs (miRNAs), typically 20–25 nucleotides in length, that mediate post-transcriptional regulation by binding to complementary sequences in the 3’-untranslated region (3’UTR) of target mRNAs [10, 11]. These molecules are implicated in diverse cardiac pathological conditions, including cardiac hypertrophy [12], heart failure [13], and myocardial ischemia and reperfusion injury [14]. Accumulating evidence further underscores the importance of miRNAs in modulating VSMC function [15]. For example, miR-181b and miR-204 suppress VSMC proliferation and migration via the β-ARR2/p-ERK1/2 pathway, highlighting a potential therapeutic avenue for atherosclerosis [16]. In addition, miR-223 promotes the progression of coronary artery lesions by regulating PDGFRβ signaling [17]. Previous reports indicate miR-4443 contributes to esophageal squamous cell carcinoma [18] and colorectal cancer [19]. In atrial fibrillation, this miRNA targets THBS1 to modulate the TGF-β1/α-SMA/collagen pathway, thereby restraining cardiac fibroblast proliferation [20]. This pathway also constitutes one of the core mechanisms underlying ventricular remodeling, myocardial fibrosis, and the progression toward heart failure following CHD. Moreover, in heart failure research, miR‑4443 has been identified as a key miRNA regulating the TAP1 gene, and an effective diagnostic model has been constructed based on it [21]. It participates in the hypoxic response, metabolic reprogramming, and inflammatory regulation, processes that play critical roles in ischemic injury, metabolic dysfunction, and inflammatory responses associated with CHD. Despite these findings, the precise function of miR-4443 in the pathogenesis of coronary heart disease remains incompletely characterized. This study therefore aimed to examine how miR-4443 influences VSMC biological activities and to explore its mechanistic basis in CHD. Materials and methods Patients and specimens A total of 200 patients diagnosed with CHD based on standard criteria [22]. were recruited. Written informed consent was obtained from all participants, and the study was approved by the Ethics Committee of CANGZHOU CENTRAL HOSPITAL. Peripheral blood was drawn from each subject, and serum was isolated within two hours and stored at -80 °C until analysis. Inclusion criteria were as follows: (a) presence of unexplained chest pain or suspected cardiac symptoms (e.g., angina pectoris or severe ventricular arrhythmia); (b) absence of severe infection, inflammatory or autoimmune diseases; (c) no history of vascular revascularization (including PCI or coronary artery bypass grafting (CABG); and (d) no history of hematologic malignancy or solid tumor. Exclusion criteria comprised: (a) history of congenital heart disease, cardiomyopathy, or vasospastic angina; (b) contraindications to coronary angiography; (c) receipt of immunosuppressive therapy within the past 3 months; (d) inability to attend regular follow-up visits; and (e) pregnancy or lactation. Patients were followed for 36 months. We retrospectively collected data on major adverse cardiovascular events (MACE) during the follow-up period, comprising cardiovascular death, myocardial infarction, unplanned revascularization, and hospitalizations for cardiovascular causes. Cell culture and ox-LDL treatment Human vascular smooth muscle cells (VSMCs; ATCC, Manassas, VA, USA) were cultured at 37 °C with 5% CO₂ in DMEM supplemented with 10% FBS (PAN Biotech, Germany) and 1% penicillin‑streptomycin. To simulate atherosclerotic conditions in vitro, cells were exposed to 20 µg/mL ox-LDL for 24 h [23]. Treated VSMCs were then used to evaluate miR-4443 expression and functional phenotypes. Cell transfection miR-4443 mimic (5’-UUGGAGGGGUGGGUUUU-3’), miR-4443 inhibitor (5’-AAAACC CACCCCTCCAA-3’), small interfering RNA targeting TIMP2 (si-TIMP2, 5’-TTGAGATTATCATAAGAG-3’) and negative control were synthesized by GenePharma. Transfection was performed using Lipofectamine 2000 according to the manufacturer’s protocol. Cells were harvested 48 h post-transfection for subsequent experiments. RT-qPCR Total RNA was extracted using Trizol™ Reagent (Invitrogen, USA). cDNA was synthesized using a reverse transcription kit. Quantitative PCR amplification was performed on a real-time quantitative PCR system (Bioneer, Korea), with GAPDH or U6 serving as endogenous references. The relative expression levels of miR-4443 and TIMP2 were determined using the 2−ΔΔCT method. The primer sequences used for GAPDH, U6, miR-4443, and TIMP2 are provided in Supplementary Table 1. CCK-8 Cell proliferation was assessed using the CCK-8 assay. VSMC were seeded into 96-well plates at a density of 5 × 10³ cells per well. After 24 h of treatment, CCK-8 reagent (10 µL/well) was added, followed by incubation at 37 °C for 2 h. Absorbance was then measured at a wavelength of 450 nm using a microplate reader. Transwell assay Cell migration was assessed using Transwell chambers (8.0-µm pores). PDGF-BB-treated VSMCs (20 ng/mL) were placed in serum-free upper chambers, with 20% FBS medium below. After 4 h, non-migrated cells were removed. Migrated cells were fixed with 4% paraformaldehyde, stained, and counted from five random fields. Dual luciferase reporter gene assay VSMCs were plated in 24-well plates 24 h before transfection. Wild-type and mutant TIMP2 3’UTR luciferase vectors (Genomeditech) were co-transfected with miR-4443 mimics or controls using Lipofectamine 2000. Luciferase activity was measured 48 h post-transfection. Bioinformatics analysis Potential targets of miR-4443 were initially predicted using the miRDB database. Candidate genes were then screened and prioritized according to their predicted binding scores. Statistical analysis Data were analyzed using SPSS 24.0 and GraphPad Prism 9.0. Study participants were stratified into high- and low-expression groups based on the median level of miR-4443. Normally distributed continuous data are presented as mean ± standard deviation and compared between groups using the two-sample t-test. Categorical data are expressed as counts and compared using the chi-square test. Survival rates were estimated by the Kaplan-Meier method, and HR with 95% CI were calculated using univariate and multivariate Cox proportional hazards models. Differences between two groups were assessed with Student’s t-test, while comparisons among multiple groups were performed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. Pearson correlation analysis was conducted to evaluate the association between miR-4443 and TIMP2. P < 0.05 (two-tailed) was considered significant. Results Expression of miR-4443 and its association with clinical parameters in patients with CHD The serum levels of miR-4443 demonstrated a significant elevation in CHD patients relative to healthy controls (Fig. 1A). Study participants were dichotomized into high- (n = 120) and low-expression (n = 80) groups according to the median miR-4443 level. Relative to the low-expression group, the high-expression cohort demonstrated elevated BMI (P < 0.0001), LDL-C (P < 0.0001), FBG (P < 0.0001), and CRP (P < 0.0001). No significant differences were observed between the two groups in terms of age, gender, smoking history, or biochemical parameters such as TC, HDL‑C, and TG (all P > 0.05). The distribution of disease subtypes also showed no significant intergroup difference: the proportions of SAP, UAP, and AMI were 35.0%, 37.5%, and 27.5% in the low-expression group, versus 37.5%, 36.7%, and 25.8% in the high-expression group (P > 0.05). Comprehensive data are summarized in Table 1. Fig. 1miR-4443 was upregulated in patients with coronary heart disease. (A) The expression level of miR-4443 in the serum of CHD and healthy volunteers was detected by RT-qPCR. (B) RT-qPCR analysis of miR-4443 expression in VSMC with and without ox-LDL treatment. (C) Kaplan-Meier survival curves of miR-4443 high expression group and low expression group. All the experiments were independently repeated three times (n = 3). ***P < 0.001 miR-4443 was upregulated in patients with coronary heart disease. (A) The expression level of miR-4443 in the serum of CHD and healthy volunteers was detected by RT-qPCR. (B) RT-qPCR analysis of miR-4443 expression in VSMC with and without ox-LDL treatment. (C) Kaplan-Meier survival curves of miR-4443 high expression group and low expression group. All the experiments were independently repeated three times (n = 3). ***P < 0.001 Table 1Baseline demographics of study population by miR-4443FactorsHigh expression(n = 120)Low expression(n = 80)(n=)P valueAge (years)63.81 ± 13.1362.09 ± 11.930.644Gender (female/male)46/7429/510.585BMI (kg/m2)27.35 ± 3.5824.23 ± 3.59< 0.0001Smoking57 (47.5%)39 (48.7%)0.767TC (mmol/L)4.73 ± 1.114.13 ± 0.970.201HDL-C (mmol/L)1.10 ± 0.271.38 ± 0.340.162LDL-C (mmol/L)3.24 ± 0.71 junction2.75 ± 0.25< 0.0001TG (mmol/L)1.67 ± 0.79 lower1.39 ± 0.780.651FBG (mmol/L)5.88 ± 3.215.20 ± 1.30< 0.0001CRP (mg/L)7.98 ± 1.495.19 ± 0.51< 0.0001Hypertension41 (34.2%)23 (28.7%)0.386Diabetes24 (20.0%)15 (18.7%)0.241SAP45 (37.5%)28 (35.0%)0.721UAP44 (36.7%)30 (37.5%)0.905AMI31 (25.8%)22 (27.5%)0.795BMI: body mass index; TC: total cholesterol; HDL-C: high‐density lipoprotein cholesterol; LDL‐C: low‐density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; CRP: C‐reactive protein; SAP: Stable Angina Pectoris; UAP: Unstable Angina Pectoris; AMI: acute myocardial infarction Table 1Baseline demographics of study population by miR-4443FactorsHigh expression(n = 120)Low expression(n = 80)(n=)P valueAge (years)63.81 ± 13.1362.09 ± 11.930.644Gender (female/male)46/7429/510.585BMI (kg/m2)27.35 ± 3.5824.23 ± 3.59< 0.0001Smoking57 (47.5%)39 (48.7%)0.767TC (mmol/L)4.73 ± 1.114.13 ± 0.970.201HDL-C (mmol/L)1.10 ± 0.271.38 ± 0.340.162LDL-C (mmol/L)3.24 ± 0.71 junction2.75 ± 0.25< 0.0001TG (mmol/L)1.67 ± 0.79 lower1.39 ± 0.780.651FBG (mmol/L)5.88 ± 3.215.20 ± 1.30< 0.0001CRP (mg/L)7.98 ± 1.495.19 ± 0.51< 0.0001Hypertension41 (34.2%)23 (28.7%)0.386Diabetes24 (20.0%)15 (18.7%)0.241SAP45 (37.5%)28 (35.0%)0.721UAP44 (36.7%)30 (37.5%)0.905AMI31 (25.8%)22 (27.5%)0.795BMI: body mass index; TC: total cholesterol; HDL-C: high‐density lipoprotein cholesterol; LDL‐C: low‐density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; CRP: C‐reactive protein; SAP: Stable Angina Pectoris; UAP: Unstable Angina Pectoris; AMI: acute myocardial infarction Baseline demographics of study population by miR-4443 BMI: body mass index; TC: total cholesterol; HDL-C: high‐density lipoprotein cholesterol; LDL‐C: low‐density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; CRP: C‐reactive protein; SAP: Stable Angina Pectoris; UAP: Unstable Angina Pectoris; AMI: acute myocardial infarction Association between miR-4443 expression and prognosis in patients with CHD Kaplan-Meier curves stratified by miR-4443 expression revealed a significantly higher cumulative incidence of MACE in the high-expression group compared to the low-expression group (Fig. 1B). Univariate Cox regression identified elevated miR-4443 expression as predictive of increased MACE risk in CHD patients (HR = 3.005, 95% CI:1.232–7.327, P = 0.016). Other significant risk factors included overweight/obesity (HR = 2.182, 95% CI:1.005–4.740, P = 0.049), high LDL-C (HR = 2.596, 95% CI:1.195–5.638, P = 0.016), and high CRP (HR = 2.240, 95% CI:1.054–4.762, P = 0.036) were also identified as risk factors for adverse outcomes. Multivariate analysis subsequently established high miR-4443 expression (P = 0.026) as prognostic predictors (Table 2). Table 2Univariate and multivariate analyses of major MACE in patients with CHD during follow-upVariableUnivariate analysisMultivariate analysisHR95% CIP-valueHR95% CIP-valuemiR-44433.0051.232–7.3270.016*2.8121.130–6.9970.026*Gender1.5050.740–3.0600.259Age0.8980.443–1.8220.766BMI2.1821.005–4.7400.049*2.0990.958–4.5990.064Smoking1.2240.603–2.4830.576TC1.2590.620–2.5540.524HDL-C1.2950.638–2.6270.474LDL-C2.5961.195–5.6380.016*2.0900.945–4.6210.069TG1.3350.648–2.7980.057FBG1.0590.523–2.1440.874CRP2.2401.054–4.7620.036*2.0640.967–4.4090.061MACE: major adverse cardiovascular events; BMI: body mass index; TC: total cholesterol; HDL-C: high‐density lipoprotein cholesterol; LDL‐C: low‐density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; CRP: C‐reactive protein; SAP: Stable Angina Pectoris; UAP: Unstable Angina Pectoris; AMI: acute myocardial infarction Table 2Univariate and multivariate analyses of major MACE in patients with CHD during follow-upVariableUnivariate analysisMultivariate analysisHR95% CIP-valueHR95% CIP-valuemiR-44433.0051.232–7.3270.016*2.8121.130–6.9970.026*Gender1.5050.740–3.0600.259Age0.8980.443–1.8220.766BMI2.1821.005–4.7400.049*2.0990.958–4.5990.064Smoking1.2240.603–2.4830.576TC1.2590.620–2.5540.524HDL-C1.2950.638–2.6270.474LDL-C2.5961.195–5.6380.016*2.0900.945–4.6210.069TG1.3350.648–2.7980.057FBG1.0590.523–2.1440.874CRP2.2401.054–4.7620.036*2.0640.967–4.4090.061MACE: major adverse cardiovascular events; BMI: body mass index; TC: total cholesterol; HDL-C: high‐density lipoprotein cholesterol; LDL‐C: low‐density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; CRP: C‐reactive protein; SAP: Stable Angina Pectoris; UAP: Unstable Angina Pectoris; AMI: acute myocardial infarction Univariate and multivariate analyses of major MACE in patients with CHD during follow-up MACE: major adverse cardiovascular events; BMI: body mass index; TC: total cholesterol; HDL-C: high‐density lipoprotein cholesterol; LDL‐C: low‐density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; CRP: C‐reactive protein; SAP: Stable Angina Pectoris; UAP: Unstable Angina Pectoris; AMI: acute myocardial infarction miR-4443 promoted VSMC proliferation and migration To further investigate its expression changes in VSMC, we employed an in vitro model mimicking atherosclerotic conditions through 20 µg/mL ox-LDL treatment. As determined by RT-qPCR, ox-LDL treatment led to a prominent induction of miR-4443 expression in ox-LDL-treated VSMCs (Fig. 1C), indicating the successful establishment of the cellular model. This investigation examined the influence of miR-4443 on VSMC proliferation and migratory capacity. Cells were transfected with miR-4443 mimics or inhibitor. Transfection with the miR-4443 mimic significantly increased miR-4443 expression levels in VSMC (Fig. 2A). Functional assessment via CCK-8 assay revealed that miR-4443 overexpression notably enhanced cellular proliferation relative to control group. Similarly (Fig. 2B), Transwell assays indicated a significant increase in VSMC migration following miR-4443 overexpression (Fig. 2C). Conversely, transfection with the miR-4443 inhibitor significantly suppressed endogenous miR-4443 expression (Fig. 2D). CCK-8 analysis demonstrated that miR-4443 knockdown considerably attenuated proliferative capacity (Fig. 2E), while Transwell experiments confirmed a significant reduction in cell migration following miR-4443 inhibition (Fig. 2F). Fig. 2miR-4443 promotes VSMC proliferation. RT-qPCR was used to detect the level of miR-4443 in VSMC after transfection with miR-4443 mimics (A) and inhibitors (D). The proliferation of VSMC after transfection of miR-4443 mimics (B) and inhibitor (E) was detected by CCK-8 assay. The migration of VSMCs after transfection of miR-4443 mimics (C) and inhibitor (F) was detected by Transwell assay. All the experiments were independently repeated three times (n = 3). ** P < 0.01, ***P < 0.001 miR-4443 promotes VSMC proliferation. RT-qPCR was used to detect the level of miR-4443 in VSMC after transfection with miR-4443 mimics (A) and inhibitors (D). The proliferation of VSMC after transfection of miR-4443 mimics (B) and inhibitor (E) was detected by CCK-8 assay. The migration of VSMCs after transfection of miR-4443 mimics (C) and inhibitor (F) was detected by Transwell assay. All the experiments were independently repeated three times (n = 3). ** P < 0.01, ***P < 0.001 TIMP2 is the direct target gene of miR-4443 Bioinformatic prediction using the miRDB database identified TIMP2 as a potential target gene of miR-4443, which is downregulated in CHD, and sequence analysis suggested a binding site between them (Fig. 3A). Experimentally, RT-qPCR confirmed substantially reduced TIMP2 mRNA levels in CHD patients relative to healthy controls (Fig. 3B). Consistently, a significant decrease in TIMP2 expression was also observed in ox‑LDL‑treated cells (Fig. 3C). To confirm direct targeting, we generated TIMP2 3’UTR luciferase constructs in both wild-type and mutated configurations. The dual-luciferase assay demonstrated that miR-4443 overexpression dramatically suppressed luciferase activity specifically in wild-type transfectants, while no such effect was observed with the mutant construct (Fig. 3D), confirming TIMP2 as a direct target. Pearson correlation analysis further supported a significant inverse relationship between miR-4443 and TIMP2 expression levels (Fig. 3E). Fig. 3miR-4443 directly targets TIMP2. (A) Binding site between miR-4443 and TIMP2. (B) The expression level of TIMP2 in medium VSMC was detected by RT-qPCR. (C) The dual luciferase reporter assay confirmed the targeting effect of miR-4443 on TIMP2. (D) Correlation analysis was used to analyze the relationship between miR-4443 and TIMP2. All the experiments were independently repeated three times (n = 3). ***P < 0.001 miR-4443 directly targets TIMP2. (A) Binding site between miR-4443 and TIMP2. (B) The expression level of TIMP2 in medium VSMC was detected by RT-qPCR. (C) The dual luciferase reporter assay confirmed the targeting effect of miR-4443 on TIMP2. (D) Correlation analysis was used to analyze the relationship between miR-4443 and TIMP2. All the experiments were independently repeated three times (n = 3). ***P < 0.001 miR-4443 regulates VSMC proliferation and migration by targeting TIMP2 Rescue experiments were conducted to determine whether the regulatory role of miR-4443 on VSMC is mediated through the suppression of TIMP2. The miR-4443 inhibitor markedly elevated TIMP2 expression upon transfection. Co-transfection with si-TIMP2 effectively reversed this induction, restoring TIMP2 to baseline levels (Fig. 4A). CCK-8 assays demonstrated that knockdown resulted in a significant reduction in cell proliferation, which was partially rescued by co-transfection with si-TIMP2 (Fig. 4B). Transwell migration assays further confirmed that co-transfection with si-TIMP2 significantly attenuated the reduction in the number of migrating cells caused by miR-4443 silencing (Fig. 4C). These results demonstrate that miR-4443 regulates VSMC proliferation and migration by negatively modulating TIMP2. Fig. 4Rescue experiments. (A) VSMC were transfected with negative control (NC), miR-4443 inhibitor, or miR-4443 inhibitor + si-TIMP2. (B) The suppression of VSMC proliferation following miR-4443 knockdown was significantly reversed by co-transfection with si-TIMP2. (C) The inhibitory effect of miR-4443 inhibitor on VSMC migration was partially restored when TIMP2 was simultaneously knocked down. All the experiments were independently repeated three times (n = 3). ** P < 0.01, ***P < 0.001 Rescue experiments. (A) VSMC were transfected with negative control (NC), miR-4443 inhibitor, or miR-4443 inhibitor + si-TIMP2. (B) The suppression of VSMC proliferation following miR-4443 knockdown was significantly reversed by co-transfection with si-TIMP2. (C) The inhibitory effect of miR-4443 inhibitor on VSMC migration was partially restored when TIMP2 was simultaneously knocked down. All the experiments were independently repeated three times (n = 3). ** P < 0.01, ***P < 0.001 Discussion CHD represents a major cardiovascular disorder exhibiting rising incidence and mortality rates worldwide, and its pathological mechanism research and optimization of prevention and treatment strategies have become the focus of clinical attention [24]. At present, it is recognized that coronary atherosclerosis is the main pathological basis of CHD, which begins with vascular endothelial dysfunction and is accompanied by phenotypic transformation and migration of VSMC [25]. Many studies have pointed out that VSMC plays a central role in the formation, development and stability maintenance of atherosclerotic plaque [26, 27]. Consequently, this investigation was prompted to clarify the functions of miR-4443 and TIMP2 in VSMC, findings that may hold therapeutic relevance for CHD management. In recent years, miRNAs have emerged as a novel class of regulatory molecules and disease biomarkers. Their stability in circulation and their ability to undergo changes in the early stages of disease make them promising candidates for clinical biomarker applications [28], Prior studies have demonstrated the diagnostic and prognostic value of specific miRNAs, such as miR-155, and miR-21 in patients with CHD [29, 30]. This study focused on miR-4443 to investigate its clinical significance in patients with CHD. We observed a significant upregulation of miR-4443 in the peripheral blood of CHD patients compared to healthy controls. This finding aligns with previously reported patterns of upregulated miRNAs in CHD, such as miR-26-3p and miR-145-5p [31], suggesting a potential role for miR-4443 in the pathogenesis of CHD. Patients were dichotomized into high- and low-expression groups according to the median miR-4443 level, we found that the high-expression group exhibited elevated levels of BMI, LDL-C, FBG, and CRP. These parameters are established cardiovascular risk factors closely associated with metabolic dysfunction and inflammatory states [32, 33], In univariate analysis, miR-4443, BMI, LDL-C, and CRP were all significantly associated with MACE risk. Following multivariable adjustment, only elevated miR-4443 expression remained an independent predictor. A significantly reduced MACE-free survival rate was observed in the high miR-4443 expression group by Kaplan-Meier analysis. At present, it is recognized that coronary atherosclerosis is the main pathological basis of CHD, which begins with vascular endothelial dysfunction and is accompanied by phenotypic transformation and migration of VSMC [25], VSMCs are widely recognized to be pivotal in atherogenesis, contributing to both the progression and stability of atherosclerotic plaques [26, 27]. Consequently, this investigation was prompted to clarify the functions of miR-4443 and TIMP2 in VSMC, findings that may hold therapeutic relevance for CHD management. We established an in vitro model using ox-LDL to induce VSMCs and observed a significant upregulation of miR-4443 expression. Subsequent functional assays confirmed that miR-4443 overexpression enhances VSMC proliferation and migration, whereas its knockdown inhibited these cellular activities. These findings suggest that miR-4443 may contribute to the development of atherosclerosis by regulating VSMC proliferation and migration. To explore the underlying mechanism, bioinformatics analysis designated TIMP2 as a putative target of miR-4443. The TIMP protein family includes four members, TIMP1, TIMP2, TIMP3, and TIMP4, which are highly conserved in structure and usually consist of 184–194 amino acids with a molecular weight of about 21 kDa [34]. Different TIMP members have different inhibitory activities on matrix metalloproteinases and then participate in the regulation of extracellular matrix remodeling, inflammatory response, vascular remodeling, and other pathophysiological processes [35]. Evidence from previous investigations indicates that TIMP2 expression is detectable across multiple cellular components within atherosclerotic plaques, but the expression level in diseased vessels is lower than that in healthy vessels [36]. The direct targeting interaction between miR-4443 and a specific site within the TIMP2 3’UTR, resulting in translational suppression, verification was obtained through dual-luciferase reporter assays. In addition, miR-4443 was significantly negatively correlated with TIMP2 expression in CHD patient samples, further supporting the regulatory relationship between the two in vivo. To investigate whether miR-4443 modulates VSMC function through TIMP2 targeting, we conducted reversion experiments to verify the functional role. Knockdown of miR-4443 markedly elevated TIMP2 expression and suppressed VSMC proliferation and migration. However, co-transfection of si-TIMP2 partially reversed this effect. These results suggested that miR-4443 promoted VSMC proliferation and migration mainly by negatively regulating TIMP2 expression. This study has several limitations. Firstly, it is a retrospective investigation with a relatively small sample size; future validation through multicenter, large-scale prospective studies is warranted. Secondly, prior research has demonstrated that cardiac endothelial-specific overexpression of miR-187 in a conditional knock-in mouse model successfully induced ventricular septal defects and cardiac hypoplasia resembling human tetralogy of Fallot [37]. These findings highlight the indispensable role of in vivo experiments in systematically evaluating therapeutic strategies and elucidating the molecular mechanisms underlying coronary artery disease. Due to constraints in the research timeline and experimental conditions, relevant animal in vivo experiments were not conducted in the present study. Subsequent work will involve establishing appropriate in vivo models to further validate the biological functions and therapeutic potential of miR‑4443, thereby providing a stronger experimental foundation for future translational research. This study demonstrates upregulated miR-4443 expression in CHD patients, and its expression level is related to abnormal blood lipid indexes and poor prognosis of patients, supporting its potential utility as a prognostic biomarker. Mechanistically, miR-4443 promotes VSMC proliferation and migration by directly targeting TIMP2, indicating that miR-4443/TIMP2 axis represents a promising target for novel molecular therapies in CHD. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1